Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
2.285
Zitationen
18
Autoren
2003
Jahr
Abstract
Activating mutations of KIT or PDGFRA are found in the vast majority of GISTs, and the mutational status of these oncoproteins is predictive of clinical response to imatinib. PDGFRA mutations can explain response and sensitivity to imatinib in some GISTs lacking KIT mutations.
Ähnliche Arbeiten
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 · 7.177 Zit.
Comprehensive molecular characterization of gastric adenocarcinoma
2014 · 6.368 Zit.
WHO Classification of Tumours of the Digestive System
2010 · 4.816 Zit.
Gastric cancer
2020 · 4.614 Zit.
Gain-of-Function Mutations of c- <i>kit</i> in Human Gastrointestinal Stromal Tumors
1998 · 4.456 Zit.
Autoren
- Michael C. Heinrich
- Christopher L. Corless
- George D. Demetri
- Charles D. Blanke
- Margaret von Mehren
- Heikki Joensuu
- Laura McGreevey
- Chang-Jie Chen
- Annick D. Van den Abbeele
- Brian Druker
- Beate Kiese
- Burton Eisenberg
- Peter Roberts
- Samuel Singer
- Christopher D.�M. Fletcher
- Sandra Silberman
- Saša Dimitrijević
- Jonathan A. Fletcher